ZimVie, Inc.

As of October 10, 2025, ZimVie, Inc. shows a bullish trend supported by positive MACD and Bollinger Bands, despite a bearish weekly RSI and mixed KST signals, with a year-to-date return of 35.99% significantly outperforming the S&P 500's 11.41%.

As of October 10, 2025, ZimVie, Inc. shows a bullish trend with moderate strength, supported by positive MACD and moving averages, despite a bearish weekly RSI and mixed KST signals, and has outperformed the S&P 500 with a year-to-date return of 35.91%.

As of October 10, 2025, ZimVie, Inc. has a bullish technical trend supported by strong indicators, despite some short-term weakness in the weekly RSI, and has significantly outperformed the S&P 500 with a year-to-date return of 35.91%.

As of August 18, 2025, ZimVie, Inc. shows a bullish technical trend supported by positive weekly MACD and moving averages, despite a bearish weekly RSI, with a year-to-date return of 35.48% compared to the S&P 500's 12.22%.

As of August 10, 2022, ZimVie, Inc. is considered risky and overvalued with a Price to Book Value of 0.66 and an EV to EBITDA of 11.89, despite a strong year-to-date return of 35.48%, which lags behind the S&P 500's three-year performance.

As of August 10, 2022, ZimVie, Inc. is classified as "risky" and overvalued, with concerning financial ratios, a year-to-date return of -37.99%, and underperformance compared to peers like AngioDynamics and Sanara MedTech.

As of June 13, 2025, ZimVie, Inc. exhibits a bearish trend with mixed signals from indicators, including a bearish stance in Bollinger Bands and moving averages, despite some mild bullishness in the weekly MACD and KST.

ZimVie, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $112 million and a net loss of $3 million as of March 2025. It has a market cap of $244.31 million and key metrics indicating a loss-making status with no dividend yield.

As of Jun 18, ZimVie, Inc. has a market capitalization of 244.31 million, with net sales of 443.55 million and a net profit of -24.89 million over the latest four quarters.